Clinical benefits of adding olanzapine to 5-HT 3 receptor antagonist, NK 1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology

Olanzapine is an atypical antipsychotic drug used for chemotherapy-induced nausea and vomiting. It is particularly effective in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy (HEC). However, it has side effects, such as hyperglycemia and somnolence, the efficacy and...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of clinical oncology 2025-01, Vol.30 (1), p.27
Hauptverfasser:	Murakami, Michiyasu, Miyata, Yoshiharu, Nakashima, Kazuhisa, Abe, Masakazu, Nishimura, Junichi, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K, Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-Il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakamura, Naoki, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Okita, Kenji, Yamamoto, Nobuyuki, Aogi, Kenjiro, Nakajima, Takako Eguchi
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!